A new UK study shows that vaccinating pregnant women against RSV has led to a staggering 72% drop in hospitalizations of ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

Researchers from Cornell and Northwestern universities have developed a rapid, cell-free method for building nanoparticle ...

Respiratory syncytial virus (RSV) causes symptoms similar to the common cold. But in older adults and those with certain medical conditions, the virus can increase the risk of serious illnesses.

Respiratory syncytial virus (RSV) infections can lead to serious complications, particularly in infants and older adults aged 75 years and above. Recent advancements in vaccine trials for older ...

New data for AREXVY, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease ...

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons ...

Learn about Respiratory Syncytial Virus (RSV), its symptoms, treatment, and prevention. Get expert advice on how to protect vulnerable populations from this viral infection.

INTRODUCTION RESPIRATORY SYNCYTIAL VIRUS (RSV) is a pneumovirus frequently associated with respiratory illnesses. 1-3 While RSV has been known to cause serious complications in infants and young ...

The RSV vaccine can protect against respiratory syncytial virus infections, especially in infants and people at high risk.

Respiratory syncytial virus (RSV): What to know, including symptoms, how to know when it’s serious, who has a high risk, treatment, prevention, and more.